nodes	percent_of_prediction	percent_of_DWPC	metapath
Idarubicin—Topoisomerase Inhibitors—Teniposide—lymphatic system cancer	0.396	0.569	CiPCiCtD
Idarubicin—Topoisomerase Inhibitors—Mitoxantrone—lymphatic system cancer	0.3	0.431	CiPCiCtD
Idarubicin—TOP2A—Teniposide—lymphatic system cancer	0.0867	0.377	CbGbCtD
Idarubicin—TOP2A—Mitoxantrone—lymphatic system cancer	0.0607	0.264	CbGbCtD
Idarubicin—ABCC1—Mitoxantrone—lymphatic system cancer	0.0336	0.146	CbGbCtD
Idarubicin—ABCC1—Vincristine—lymphatic system cancer	0.0231	0.101	CbGbCtD
Idarubicin—ABCC1—Methotrexate—lymphatic system cancer	0.014	0.0609	CbGbCtD
Idarubicin—CYP2C9—Teniposide—lymphatic system cancer	0.012	0.0519	CbGbCtD
Idarubicin—TOP2A—Etoposide—Teniposide—lymphatic system cancer	0.000329	0.195	CbGdCrCtD
Idarubicin—Ulcer—Bleomycin—lymphatic system cancer	0.000271	0.00376	CcSEcCtD
Idarubicin—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.000271	0.00376	CcSEcCtD
Idarubicin—Necrosis—Mitoxantrone—lymphatic system cancer	0.000265	0.00368	CcSEcCtD
Idarubicin—Extravasation—Carmustine—lymphatic system cancer	0.000256	0.00356	CcSEcCtD
Idarubicin—TOP2A—Podofilox—Teniposide—lymphatic system cancer	0.000251	0.149	CbGdCrCtD
Idarubicin—Extravasation—Vincristine—lymphatic system cancer	0.000244	0.0034	CcSEcCtD
Idarubicin—Pericarditis—Methotrexate—lymphatic system cancer	0.000239	0.00333	CcSEcCtD
Idarubicin—Alopecia—Mechlorethamine—lymphatic system cancer	0.000239	0.00332	CcSEcCtD
Idarubicin—Extravasation—Mitoxantrone—lymphatic system cancer	0.000238	0.00331	CcSEcCtD
Idarubicin—TOP2A—Vindesine—Vincristine—lymphatic system cancer	0.000237	0.14	CbGdCrCtD
Idarubicin—Pancytopenia—Teniposide—lymphatic system cancer	0.000237	0.00329	CcSEcCtD
Idarubicin—Dehydration—Fludarabine—lymphatic system cancer	0.000236	0.00328	CcSEcCtD
Idarubicin—Neutropenia—Teniposide—lymphatic system cancer	0.000233	0.00324	CcSEcCtD
Idarubicin—Hyperuricaemia—Vincristine—lymphatic system cancer	0.00023	0.0032	CcSEcCtD
Idarubicin—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.000224	0.00311	CcSEcCtD
Idarubicin—Ulcer—Mitoxantrone—lymphatic system cancer	0.00022	0.00305	CcSEcCtD
Idarubicin—Blood uric acid increased—Vincristine—lymphatic system cancer	0.000217	0.00302	CcSEcCtD
Idarubicin—Stomatitis—Teniposide—lymphatic system cancer	0.000217	0.00301	CcSEcCtD
Idarubicin—Phlebitis—Bleomycin—lymphatic system cancer	0.000216	0.003	CcSEcCtD
Idarubicin—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.000212	0.00294	CcSEcCtD
Idarubicin—Leukopenia—Mechlorethamine—lymphatic system cancer	0.000211	0.00293	CcSEcCtD
Idarubicin—Pancytopenia—Fludarabine—lymphatic system cancer	0.000208	0.00289	CcSEcCtD
Idarubicin—Neutropenia—Fludarabine—lymphatic system cancer	0.000205	0.00285	CcSEcCtD
Idarubicin—Neoplasm—Carmustine—lymphatic system cancer	0.000202	0.00281	CcSEcCtD
Idarubicin—Haemoglobin—Teniposide—lymphatic system cancer	0.000201	0.00279	CcSEcCtD
Idarubicin—Haemorrhage—Teniposide—lymphatic system cancer	0.0002	0.00277	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.000199	0.00277	CcSEcCtD
Idarubicin—Sepsis—Carmustine—lymphatic system cancer	0.000194	0.0027	CcSEcCtD
Idarubicin—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.000193	0.00268	CcSEcCtD
Idarubicin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.000192	0.00267	CcSEcCtD
Idarubicin—Myocardial infarction—Fludarabine—lymphatic system cancer	0.000191	0.00266	CcSEcCtD
Idarubicin—Infection—Mechlorethamine—lymphatic system cancer	0.000191	0.00265	CcSEcCtD
Idarubicin—Stomatitis—Fludarabine—lymphatic system cancer	0.00019	0.00265	CcSEcCtD
Idarubicin—Phlebitis—Carmustine—lymphatic system cancer	0.000188	0.00262	CcSEcCtD
Idarubicin—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.000188	0.00262	CcSEcCtD
Idarubicin—Thrombophlebitis—Carmustine—lymphatic system cancer	0.000187	0.0026	CcSEcCtD
Idarubicin—Mucosal inflammation—Methotrexate—lymphatic system cancer	0.000187	0.0026	CcSEcCtD
Idarubicin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.000187	0.0026	CcSEcCtD
Idarubicin—Flushing—Teniposide—lymphatic system cancer	0.000185	0.00257	CcSEcCtD
Idarubicin—Anorexia—Mechlorethamine—lymphatic system cancer	0.000183	0.00255	CcSEcCtD
Idarubicin—Sepsis—Mitoxantrone—lymphatic system cancer	0.00018	0.00251	CcSEcCtD
Idarubicin—Chills—Teniposide—lymphatic system cancer	0.000179	0.00249	CcSEcCtD
Idarubicin—Arrhythmia—Teniposide—lymphatic system cancer	0.000178	0.00248	CcSEcCtD
Idarubicin—Alopecia—Teniposide—lymphatic system cancer	0.000176	0.00245	CcSEcCtD
Idarubicin—Haemoglobin—Fludarabine—lymphatic system cancer	0.000176	0.00245	CcSEcCtD
Idarubicin—Haemorrhage—Fludarabine—lymphatic system cancer	0.000175	0.00244	CcSEcCtD
Idarubicin—Phlebitis—Mitoxantrone—lymphatic system cancer	0.000175	0.00243	CcSEcCtD
Idarubicin—Skin hyperpigmentation—Methotrexate—lymphatic system cancer	0.000174	0.00242	CcSEcCtD
Idarubicin—Febrile neutropenia—Methotrexate—lymphatic system cancer	0.000172	0.00239	CcSEcCtD
Idarubicin—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.000167	0.00232	CcSEcCtD
Idarubicin—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.000166	0.00231	CcSEcCtD
Idarubicin—Embolism—Methotrexate—lymphatic system cancer	0.000161	0.00224	CcSEcCtD
Idarubicin—Anaemia—Teniposide—lymphatic system cancer	0.000161	0.00223	CcSEcCtD
Idarubicin—Chills—Fludarabine—lymphatic system cancer	0.000157	0.00219	CcSEcCtD
Idarubicin—Arrhythmia—Fludarabine—lymphatic system cancer	0.000157	0.00218	CcSEcCtD
Idarubicin—Leukopenia—Teniposide—lymphatic system cancer	0.000155	0.00216	CcSEcCtD
Idarubicin—Alopecia—Fludarabine—lymphatic system cancer	0.000155	0.00215	CcSEcCtD
Idarubicin—Bone marrow depression—Methotrexate—lymphatic system cancer	0.000153	0.00213	CcSEcCtD
Idarubicin—Malnutrition—Fludarabine—lymphatic system cancer	0.000153	0.00212	CcSEcCtD
Idarubicin—Pancytopenia—Bleomycin—lymphatic system cancer	0.000153	0.00212	CcSEcCtD
Idarubicin—TOP2A—Vinorelbine—Vincristine—lymphatic system cancer	0.000149	0.0884	CbGdCrCtD
Idarubicin—Burning sensation—Methotrexate—lymphatic system cancer	0.000149	0.00207	CcSEcCtD
Idarubicin—Chest pain—Teniposide—lymphatic system cancer	0.000148	0.00205	CcSEcCtD
Idarubicin—Dehydration—Vincristine—lymphatic system cancer	0.000144	0.002	CcSEcCtD
Idarubicin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000142	0.00197	CcSEcCtD
Idarubicin—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.000141	0.00196	CcSEcCtD
Idarubicin—Anaemia—Fludarabine—lymphatic system cancer	0.000141	0.00196	CcSEcCtD
Idarubicin—Infection—Teniposide—lymphatic system cancer	0.000141	0.00196	CcSEcCtD
Idarubicin—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00014	0.00195	CcSEcCtD
Idarubicin—Dehydration—Mitoxantrone—lymphatic system cancer	0.00014	0.00195	CcSEcCtD
Idarubicin—Stomatitis—Bleomycin—lymphatic system cancer	0.00014	0.00194	CcSEcCtD
Idarubicin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000139	0.00193	CcSEcCtD
Idarubicin—Leukopenia—Fludarabine—lymphatic system cancer	0.000137	0.0019	CcSEcCtD
Idarubicin—Anorexia—Teniposide—lymphatic system cancer	0.000135	0.00188	CcSEcCtD
Idarubicin—Pancytopenia—Carmustine—lymphatic system cancer	0.000133	0.00185	CcSEcCtD
Idarubicin—Convulsion—Fludarabine—lymphatic system cancer	0.000132	0.00184	CcSEcCtD
Idarubicin—Necrosis—Methotrexate—lymphatic system cancer	0.000132	0.00183	CcSEcCtD
Idarubicin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000132	0.00183	CcSEcCtD
Idarubicin—Neutropenia—Carmustine—lymphatic system cancer	0.000131	0.00182	CcSEcCtD
Idarubicin—Haemoglobin—Bleomycin—lymphatic system cancer	0.000129	0.0018	CcSEcCtD
Idarubicin—Haemorrhage—Bleomycin—lymphatic system cancer	0.000129	0.00179	CcSEcCtD
Idarubicin—Pancytopenia—Vincristine—lymphatic system cancer	0.000127	0.00177	CcSEcCtD
Idarubicin—Neutropenia—Vincristine—lymphatic system cancer	0.000125	0.00174	CcSEcCtD
Idarubicin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000125	0.00173	CcSEcCtD
Idarubicin—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000124	0.00172	CcSEcCtD
Idarubicin—Infection—Fludarabine—lymphatic system cancer	0.000124	0.00172	CcSEcCtD
Idarubicin—Decreased appetite—Teniposide—lymphatic system cancer	0.000123	0.00171	CcSEcCtD
Idarubicin—Vomiting—Mechlorethamine—lymphatic system cancer	0.000122	0.0017	CcSEcCtD
Idarubicin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000122	0.0017	CcSEcCtD
Idarubicin—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000122	0.00169	CcSEcCtD
Idarubicin—Stomatitis—Carmustine—lymphatic system cancer	0.000122	0.00169	CcSEcCtD
Idarubicin—Rash—Mechlorethamine—lymphatic system cancer	0.000121	0.00168	CcSEcCtD
Idarubicin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000121	0.00168	CcSEcCtD
Idarubicin—Flushing—Bleomycin—lymphatic system cancer	0.000119	0.00166	CcSEcCtD
Idarubicin—Anorexia—Fludarabine—lymphatic system cancer	0.000119	0.00165	CcSEcCtD
Idarubicin—Extravasation—Methotrexate—lymphatic system cancer	0.000119	0.00165	CcSEcCtD
Idarubicin—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000118	0.00163	CcSEcCtD
Idarubicin—Myocardial infarction—Vincristine—lymphatic system cancer	0.000117	0.00163	CcSEcCtD
Idarubicin—Stomatitis—Vincristine—lymphatic system cancer	0.000116	0.00162	CcSEcCtD
Idarubicin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000116	0.00161	CcSEcCtD
Idarubicin—Chills—Bleomycin—lymphatic system cancer	0.000115	0.0016	CcSEcCtD
Idarubicin—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000115	0.00159	CcSEcCtD
Idarubicin—Nausea—Mechlorethamine—lymphatic system cancer	0.000114	0.00159	CcSEcCtD
Idarubicin—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000114	0.00158	CcSEcCtD
Idarubicin—Alopecia—Bleomycin—lymphatic system cancer	0.000114	0.00158	CcSEcCtD
Idarubicin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000113	0.00157	CcSEcCtD
Idarubicin—TOP2A—Cladribine—Fludarabine—lymphatic system cancer	0.000113	0.0669	CbGdCrCtD
Idarubicin—Haemoglobin—Carmustine—lymphatic system cancer	0.000113	0.00157	CcSEcCtD
Idarubicin—Urticaria—Teniposide—lymphatic system cancer	0.000113	0.00156	CcSEcCtD
Idarubicin—Haemorrhage—Carmustine—lymphatic system cancer	0.000112	0.00156	CcSEcCtD
Idarubicin—Abdominal pain—Teniposide—lymphatic system cancer	0.000112	0.00156	CcSEcCtD
Idarubicin—Body temperature increased—Teniposide—lymphatic system cancer	0.000112	0.00156	CcSEcCtD
Idarubicin—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.000112	0.00155	CcSEcCtD
Idarubicin—Ulcer—Methotrexate—lymphatic system cancer	0.000109	0.00152	CcSEcCtD
Idarubicin—Decreased appetite—Fludarabine—lymphatic system cancer	0.000108	0.00151	CcSEcCtD
Idarubicin—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000106	0.00147	CcSEcCtD
Idarubicin—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.000105	0.00146	CcSEcCtD
Idarubicin—Urethral disorder—Vincristine—lymphatic system cancer	0.000105	0.00146	CcSEcCtD
Idarubicin—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000105	0.00146	CcSEcCtD
Idarubicin—TOP2A—Clofarabine—Fludarabine—lymphatic system cancer	0.000104	0.0618	CbGdCrCtD
Idarubicin—Hypersensitivity—Teniposide—lymphatic system cancer	0.000104	0.00145	CcSEcCtD
Idarubicin—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000104	0.00145	CcSEcCtD
Idarubicin—Flushing—Carmustine—lymphatic system cancer	0.000104	0.00145	CcSEcCtD
Idarubicin—Anaemia—Bleomycin—lymphatic system cancer	0.000103	0.00144	CcSEcCtD
Idarubicin—TOP2A—Vinblastine—Vincristine—lymphatic system cancer	0.000103	0.0608	CbGdCrCtD
Idarubicin—Arrhythmia—Carmustine—lymphatic system cancer	0.0001	0.00139	CcSEcCtD
Idarubicin—Leukopenia—Bleomycin—lymphatic system cancer	0.0001	0.00139	CcSEcCtD
Idarubicin—Alopecia—Carmustine—lymphatic system cancer	9.92e-05	0.00138	CcSEcCtD
Idarubicin—TOP2A—Clofarabine—Cytarabine—lymphatic system cancer	9.87e-05	0.0584	CbGdCrCtD
Idarubicin—Body temperature increased—Fludarabine—lymphatic system cancer	9.85e-05	0.00137	CcSEcCtD
Idarubicin—Malnutrition—Carmustine—lymphatic system cancer	9.77e-05	0.00136	CcSEcCtD
Idarubicin—Angiopathy—Vincristine—lymphatic system cancer	9.72e-05	0.00135	CcSEcCtD
Idarubicin—Diarrhoea—Teniposide—lymphatic system cancer	9.7e-05	0.00135	CcSEcCtD
Idarubicin—Chest pain—Bleomycin—lymphatic system cancer	9.53e-05	0.00132	CcSEcCtD
Idarubicin—Alopecia—Vincristine—lymphatic system cancer	9.47e-05	0.00132	CcSEcCtD
Idarubicin—Chills—Mitoxantrone—lymphatic system cancer	9.36e-05	0.0013	CcSEcCtD
Idarubicin—Neoplasm—Methotrexate—lymphatic system cancer	9.36e-05	0.0013	CcSEcCtD
Idarubicin—Arrhythmia—Mitoxantrone—lymphatic system cancer	9.32e-05	0.0013	CcSEcCtD
Idarubicin—Alopecia—Mitoxantrone—lymphatic system cancer	9.22e-05	0.00128	CcSEcCtD
Idarubicin—Hypersensitivity—Fludarabine—lymphatic system cancer	9.18e-05	0.00128	CcSEcCtD
Idarubicin—TOP2A—Gemcitabine—Cytarabine—lymphatic system cancer	9.14e-05	0.0541	CbGdCrCtD
Idarubicin—Anaphylactic shock—Bleomycin—lymphatic system cancer	9.13e-05	0.00127	CcSEcCtD
Idarubicin—Infection—Bleomycin—lymphatic system cancer	9.07e-05	0.00126	CcSEcCtD
Idarubicin—Anaemia—Carmustine—lymphatic system cancer	9.03e-05	0.00125	CcSEcCtD
Idarubicin—Vomiting—Teniposide—lymphatic system cancer	9.01e-05	0.00125	CcSEcCtD
Idarubicin—Sepsis—Methotrexate—lymphatic system cancer	8.98e-05	0.00125	CcSEcCtD
Idarubicin—Thrombocytopenia—Bleomycin—lymphatic system cancer	8.94e-05	0.00124	CcSEcCtD
Idarubicin—Rash—Teniposide—lymphatic system cancer	8.94e-05	0.00124	CcSEcCtD
Idarubicin—Dermatitis—Teniposide—lymphatic system cancer	8.93e-05	0.00124	CcSEcCtD
Idarubicin—TOP2A—Cytarabine—Fludarabine—lymphatic system cancer	8.89e-05	0.0526	CbGdCrCtD
Idarubicin—Headache—Teniposide—lymphatic system cancer	8.88e-05	0.00123	CcSEcCtD
Idarubicin—Leukopenia—Carmustine—lymphatic system cancer	8.74e-05	0.00122	CcSEcCtD
Idarubicin—Anorexia—Bleomycin—lymphatic system cancer	8.71e-05	0.00121	CcSEcCtD
Idarubicin—Thrombophlebitis—Methotrexate—lymphatic system cancer	8.68e-05	0.00121	CcSEcCtD
Idarubicin—Anaemia—Vincristine—lymphatic system cancer	8.62e-05	0.0012	CcSEcCtD
Idarubicin—Diarrhoea—Fludarabine—lymphatic system cancer	8.52e-05	0.00118	CcSEcCtD
Idarubicin—Convulsion—Carmustine—lymphatic system cancer	8.46e-05	0.00118	CcSEcCtD
Idarubicin—Nausea—Teniposide—lymphatic system cancer	8.42e-05	0.00117	CcSEcCtD
Idarubicin—Anaemia—Mitoxantrone—lymphatic system cancer	8.39e-05	0.00117	CcSEcCtD
Idarubicin—Leukopenia—Vincristine—lymphatic system cancer	8.35e-05	0.00116	CcSEcCtD
Idarubicin—Chest pain—Carmustine—lymphatic system cancer	8.32e-05	0.00116	CcSEcCtD
Idarubicin—Leukopenia—Mitoxantrone—lymphatic system cancer	8.13e-05	0.00113	CcSEcCtD
Idarubicin—Convulsion—Vincristine—lymphatic system cancer	8.08e-05	0.00112	CcSEcCtD
Idarubicin—Decreased appetite—Bleomycin—lymphatic system cancer	7.94e-05	0.0011	CcSEcCtD
Idarubicin—Infection—Carmustine—lymphatic system cancer	7.92e-05	0.0011	CcSEcCtD
Idarubicin—Vomiting—Fludarabine—lymphatic system cancer	7.92e-05	0.0011	CcSEcCtD
Idarubicin—Convulsion—Mitoxantrone—lymphatic system cancer	7.87e-05	0.00109	CcSEcCtD
Idarubicin—Rash—Fludarabine—lymphatic system cancer	7.85e-05	0.00109	CcSEcCtD
Idarubicin—Dermatitis—Fludarabine—lymphatic system cancer	7.85e-05	0.00109	CcSEcCtD
Idarubicin—Thrombocytopenia—Carmustine—lymphatic system cancer	7.81e-05	0.00108	CcSEcCtD
Idarubicin—Headache—Fludarabine—lymphatic system cancer	7.8e-05	0.00108	CcSEcCtD
Idarubicin—Chest pain—Mitoxantrone—lymphatic system cancer	7.73e-05	0.00107	CcSEcCtD
Idarubicin—Anaphylactic shock—Vincristine—lymphatic system cancer	7.61e-05	0.00106	CcSEcCtD
Idarubicin—Anorexia—Carmustine—lymphatic system cancer	7.6e-05	0.00106	CcSEcCtD
Idarubicin—Infection—Vincristine—lymphatic system cancer	7.56e-05	0.00105	CcSEcCtD
Idarubicin—Thrombocytopenia—Vincristine—lymphatic system cancer	7.45e-05	0.00104	CcSEcCtD
Idarubicin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	7.41e-05	0.00103	CcSEcCtD
Idarubicin—Nausea—Fludarabine—lymphatic system cancer	7.4e-05	0.00103	CcSEcCtD
Idarubicin—Infection—Mitoxantrone—lymphatic system cancer	7.36e-05	0.00102	CcSEcCtD
Idarubicin—Shock—Mitoxantrone—lymphatic system cancer	7.29e-05	0.00101	CcSEcCtD
Idarubicin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	7.26e-05	0.00101	CcSEcCtD
Idarubicin—Urticaria—Bleomycin—lymphatic system cancer	7.26e-05	0.00101	CcSEcCtD
Idarubicin—Anorexia—Vincristine—lymphatic system cancer	7.25e-05	0.00101	CcSEcCtD
Idarubicin—Body temperature increased—Bleomycin—lymphatic system cancer	7.22e-05	0.001	CcSEcCtD
Idarubicin—Skin disorder—Mitoxantrone—lymphatic system cancer	7.2e-05	0.001	CcSEcCtD
Idarubicin—Anorexia—Mitoxantrone—lymphatic system cancer	7.07e-05	0.000982	CcSEcCtD
Idarubicin—Decreased appetite—Carmustine—lymphatic system cancer	6.93e-05	0.000963	CcSEcCtD
Idarubicin—Hypersensitivity—Bleomycin—lymphatic system cancer	6.73e-05	0.000935	CcSEcCtD
Idarubicin—Decreased appetite—Vincristine—lymphatic system cancer	6.62e-05	0.000919	CcSEcCtD
Idarubicin—Gastrointestinal pain—Carmustine—lymphatic system cancer	6.52e-05	0.000906	CcSEcCtD
Idarubicin—Decreased appetite—Mitoxantrone—lymphatic system cancer	6.44e-05	0.000895	CcSEcCtD
Idarubicin—TOP2A—Azacitidine—Fludarabine—lymphatic system cancer	6.37e-05	0.0377	CbGdCrCtD
Idarubicin—Body temperature increased—Carmustine—lymphatic system cancer	6.3e-05	0.000876	CcSEcCtD
Idarubicin—Abdominal pain—Carmustine—lymphatic system cancer	6.3e-05	0.000876	CcSEcCtD
Idarubicin—Gastrointestinal pain—Vincristine—lymphatic system cancer	6.22e-05	0.000865	CcSEcCtD
Idarubicin—Pancytopenia—Methotrexate—lymphatic system cancer	6.17e-05	0.000857	CcSEcCtD
Idarubicin—Neutropenia—Methotrexate—lymphatic system cancer	6.07e-05	0.000844	CcSEcCtD
Idarubicin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	6.06e-05	0.000842	CcSEcCtD
Idarubicin—TOP2A—Azacitidine—Cytarabine—lymphatic system cancer	6.02e-05	0.0356	CbGdCrCtD
Idarubicin—Body temperature increased—Vincristine—lymphatic system cancer	6.02e-05	0.000836	CcSEcCtD
Idarubicin—Abdominal pain—Vincristine—lymphatic system cancer	6.02e-05	0.000836	CcSEcCtD
Idarubicin—Urticaria—Mitoxantrone—lymphatic system cancer	5.89e-05	0.000818	CcSEcCtD
Idarubicin—Hypersensitivity—Carmustine—lymphatic system cancer	5.87e-05	0.000816	CcSEcCtD
Idarubicin—Body temperature increased—Mitoxantrone—lymphatic system cancer	5.86e-05	0.000814	CcSEcCtD
Idarubicin—Abdominal pain—Mitoxantrone—lymphatic system cancer	5.86e-05	0.000814	CcSEcCtD
Idarubicin—Vomiting—Bleomycin—lymphatic system cancer	5.81e-05	0.000807	CcSEcCtD
Idarubicin—Rash—Bleomycin—lymphatic system cancer	5.76e-05	0.0008	CcSEcCtD
Idarubicin—Dermatitis—Bleomycin—lymphatic system cancer	5.75e-05	0.0008	CcSEcCtD
Idarubicin—Stomatitis—Methotrexate—lymphatic system cancer	5.64e-05	0.000784	CcSEcCtD
Idarubicin—Hypersensitivity—Vincristine—lymphatic system cancer	5.61e-05	0.000779	CcSEcCtD
Idarubicin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	5.46e-05	0.000759	CcSEcCtD
Idarubicin—Diarrhoea—Carmustine—lymphatic system cancer	5.45e-05	0.000758	CcSEcCtD
Idarubicin—Nausea—Bleomycin—lymphatic system cancer	5.43e-05	0.000754	CcSEcCtD
Idarubicin—Haemoglobin—Methotrexate—lymphatic system cancer	5.22e-05	0.000726	CcSEcCtD
Idarubicin—Diarrhoea—Vincristine—lymphatic system cancer	5.21e-05	0.000724	CcSEcCtD
Idarubicin—Haemorrhage—Methotrexate—lymphatic system cancer	5.2e-05	0.000722	CcSEcCtD
Idarubicin—Urinary tract disorder—Methotrexate—lymphatic system cancer	5.13e-05	0.000713	CcSEcCtD
Idarubicin—Urethral disorder—Methotrexate—lymphatic system cancer	5.1e-05	0.000708	CcSEcCtD
Idarubicin—Diarrhoea—Mitoxantrone—lymphatic system cancer	5.07e-05	0.000705	CcSEcCtD
Idarubicin—Vomiting—Carmustine—lymphatic system cancer	5.07e-05	0.000705	CcSEcCtD
Idarubicin—Rash—Carmustine—lymphatic system cancer	5.03e-05	0.000699	CcSEcCtD
Idarubicin—Dermatitis—Carmustine—lymphatic system cancer	5.02e-05	0.000698	CcSEcCtD
Idarubicin—Headache—Carmustine—lymphatic system cancer	4.99e-05	0.000694	CcSEcCtD
Idarubicin—Vomiting—Vincristine—lymphatic system cancer	4.84e-05	0.000673	CcSEcCtD
Idarubicin—Rash—Vincristine—lymphatic system cancer	4.8e-05	0.000667	CcSEcCtD
Idarubicin—Dermatitis—Vincristine—lymphatic system cancer	4.79e-05	0.000666	CcSEcCtD
Idarubicin—Headache—Vincristine—lymphatic system cancer	4.77e-05	0.000663	CcSEcCtD
Idarubicin—Nausea—Carmustine—lymphatic system cancer	4.74e-05	0.000658	CcSEcCtD
Idarubicin—Angiopathy—Methotrexate—lymphatic system cancer	4.72e-05	0.000655	CcSEcCtD
Idarubicin—Vomiting—Mitoxantrone—lymphatic system cancer	4.71e-05	0.000655	CcSEcCtD
Idarubicin—Immune system disorder—Methotrexate—lymphatic system cancer	4.69e-05	0.000653	CcSEcCtD
Idarubicin—Rash—Mitoxantrone—lymphatic system cancer	4.67e-05	0.00065	CcSEcCtD
Idarubicin—Dermatitis—Mitoxantrone—lymphatic system cancer	4.67e-05	0.000649	CcSEcCtD
Idarubicin—Chills—Methotrexate—lymphatic system cancer	4.66e-05	0.000648	CcSEcCtD
Idarubicin—Headache—Mitoxantrone—lymphatic system cancer	4.64e-05	0.000645	CcSEcCtD
Idarubicin—Alopecia—Methotrexate—lymphatic system cancer	4.59e-05	0.000638	CcSEcCtD
Idarubicin—Malnutrition—Methotrexate—lymphatic system cancer	4.52e-05	0.000629	CcSEcCtD
Idarubicin—Nausea—Vincristine—lymphatic system cancer	4.52e-05	0.000628	CcSEcCtD
Idarubicin—Nausea—Mitoxantrone—lymphatic system cancer	4.4e-05	0.000612	CcSEcCtD
Idarubicin—Anaemia—Methotrexate—lymphatic system cancer	4.18e-05	0.000581	CcSEcCtD
Idarubicin—Leukopenia—Methotrexate—lymphatic system cancer	4.05e-05	0.000563	CcSEcCtD
Idarubicin—Convulsion—Methotrexate—lymphatic system cancer	3.92e-05	0.000545	CcSEcCtD
Idarubicin—Chest pain—Methotrexate—lymphatic system cancer	3.85e-05	0.000535	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	3.83e-05	0.000532	CcSEcCtD
Idarubicin—Anaphylactic shock—Methotrexate—lymphatic system cancer	3.69e-05	0.000513	CcSEcCtD
Idarubicin—Infection—Methotrexate—lymphatic system cancer	3.67e-05	0.00051	CcSEcCtD
Idarubicin—Thrombocytopenia—Methotrexate—lymphatic system cancer	3.62e-05	0.000503	CcSEcCtD
Idarubicin—Skin disorder—Methotrexate—lymphatic system cancer	3.59e-05	0.000499	CcSEcCtD
Idarubicin—Anorexia—Methotrexate—lymphatic system cancer	3.52e-05	0.000489	CcSEcCtD
Idarubicin—Decreased appetite—Methotrexate—lymphatic system cancer	3.21e-05	0.000446	CcSEcCtD
Idarubicin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	3.02e-05	0.00042	CcSEcCtD
Idarubicin—Urticaria—Methotrexate—lymphatic system cancer	2.93e-05	0.000408	CcSEcCtD
Idarubicin—Body temperature increased—Methotrexate—lymphatic system cancer	2.92e-05	0.000406	CcSEcCtD
Idarubicin—Abdominal pain—Methotrexate—lymphatic system cancer	2.92e-05	0.000406	CcSEcCtD
Idarubicin—Hypersensitivity—Methotrexate—lymphatic system cancer	2.72e-05	0.000378	CcSEcCtD
Idarubicin—Diarrhoea—Methotrexate—lymphatic system cancer	2.53e-05	0.000351	CcSEcCtD
Idarubicin—Vomiting—Methotrexate—lymphatic system cancer	2.35e-05	0.000326	CcSEcCtD
Idarubicin—Rash—Methotrexate—lymphatic system cancer	2.33e-05	0.000324	CcSEcCtD
Idarubicin—Dermatitis—Methotrexate—lymphatic system cancer	2.33e-05	0.000323	CcSEcCtD
Idarubicin—Headache—Methotrexate—lymphatic system cancer	2.31e-05	0.000322	CcSEcCtD
Idarubicin—Nausea—Methotrexate—lymphatic system cancer	2.19e-05	0.000305	CcSEcCtD
